Efficacy of once or twice weekly administration of epoetin κ in patients receiving hemodialysis: A retrospective study

Experimental and Therapeutic Medicine
Shoichiro OhtaMasahiko Tanaka

Abstract

Several clinically approved recombinant erythropoietin (rEPO) preparations, such as epoetin-β, epoetin-δ and the epoetin-α derivative, darbepoetin-α, have been commercially produced. Since the expiration of patent protection, a number of novel rEPO biosimilars have been approved on the world market. In 2010, epoetin-κ, which is biosimilar to epoetin-α, was clinically approved. Epoetin-κ is a biopharmaceutical product that is based on serum-free media following master cell bank preparation. The present study analyzes the results obtained during a six-month observation period, in which the administration of epoetin-β was switched to that of epoetin-κ. In a cohort of patients receiving chronic dialysis, who were clinically in a state of relative calm and were in control of their renal anemia, it was possible to sustain good control of the anemia by reducing the frequency of the epoetin-β administration from the conventional and empirically determined three times a week to twice a week, and further to once a week. Furthermore, the good control was maintained upon changing from the administration of epoetin-β to that of epoetin-κ. Moreover, three months subsequent to this switch, the degree of instability observed among the patients...Continue Reading

References

Jun 24, 2004·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Ronald L PisoniFriedrich K Port
Nov 6, 2004·Nature Biotechnology·Huub Schellekens
Aug 18, 2005·Kidney International·Steven Fishbane, Jeffrey S Berns
Nov 17, 2006·The New England Journal of Medicine·Ajay K SinghUNKNOWN CHOIR Investigators
Aug 21, 2007·Clinical Journal of the American Society of Nephrology : CJASN·James P EbbenAllan J Collins
Aug 28, 2007·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·UNKNOWN KDOQI
Sep 11, 2008·Journal of Pharmaceutical Sciences·Sungae S ParkBruce A Kerwin
Dec 18, 2008·Nephron. Clinical Practice·Takayuki HiraiNoriaki Yorioka
Aug 14, 2010·American Journal of Hematology·Wolfgang Jelkmann
Oct 5, 2010·Pharmaceutical Research·Vera BrinksHuub Schellekens

❮ Previous
Next ❯

Citations

Jan 19, 2018·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Ross A McKinnonJohannes B Prins

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.